Grapiprant
- Generic Name
- Grapiprant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29N5O3S
- CAS Number
- 415903-37-6
- Unique Ingredient Identifier
- J9F5ZPH7NB
- Background
Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin receptor antagonists. This type of molecules is currently in development for veterinary patients. This class of drugs was de...
- Indication
The effects of grapiprant have been investigated in the area of analgesia and anti-inflammation due to the effects that have been reported about this molecule.
...
- Associated Conditions
- -
- Associated Therapies
- -
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05041101
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Arrys Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT03658772
- Locations
- 🇺🇸
University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸New Experimental Therapeutics of San Antonio-NEXT Oncology, San Antonio, Texas, United States
🇺🇸Mayo Clinic Cancer Center - Scottsdale, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.